Calcium carbimide

Calcium carbimide
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N07BB02 (WHO) ;
Identifiers
	IUPAC name calcium 2-hydroxypropane-1,2,3-tricarboxylate; methylcyanamide;
CAS Number	8013-88-5 ;
PubChem CID	6335910;
ChemSpider	21106422 ;
UNII	ZLR270912W;
ChEMBL	ChEMBL2106095 ;
Chemical and physical data
Formula	C6H6O7.C2H4N2.Ca
Molar mass	288.268 g/mol
3D model (JSmol)	Interactive image;
	SMILES [Ca+2].O=C([O-])CC(O)(CC(=O)O)C([O-])=O.N#CNC;
	InChI InChI=1S/C6H8O7.C2H4N2.Ca/c7-3(8)1-6(13,5(11)12)2-4(9)10;1-4-2-3;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);4H,1H3;/q;;+2/p-2 ; Key:ZZOBQLACMMNMCT-UHFFFAOYSA-L ;
(what is this?) (verify)

Calcium carbimide, sold as the citrate salt under the trade name Temposil, is a disulfiram-like drug. Its effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic byproduct acetaldehyde. The result is that when alcohol is consumed by users of calcium carbimide, they experience severe reactions which include symptoms such as sweating, difficulty breathing, rapid heartbeat, rash, nausea and vomiting, and headache.

A recent 9-year study found that incorporation of supervised carbimide and the similar drug, disulfiram, into a comprehensive treatment program resulted in an abstinence rate of over 50%.[1]

Temposil was developed by Drs. Ken Ferguson and Gordon Bell, who tested the drug on themselves.[2][3][4] It was patented in 1955 by the Alcoholism Research Foundation of Ontario.[5]

References

Krampe H, Stawicki S, Wagner T, et al. (January 2006). "Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome". Alcoholism: Clinical and Experimental Research. 30 (1): 86–95. doi:10.1111/j.1530-0277.2006.00013.x. ISSN 0145-6008. PMID 16433735.
"Ogspi "PLO" 2005 Obituary". Ontario Genealogical Society.
"Deaths - Canadian Medical Association Journal". Canadian Medical Association Journal.
"Pioneer in Addiction Treatment Dr. Robert Gordon Bell Leaves Behind a Legacy of Hope and Healing" (PDF). Ontario Federation of Community Mental Health and Addiction Programs. Archived from the original (PDF) on 2014-03-11.
Booze: A Distilled History. Between The Lines. 2003. ISBN 9781896357836.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Krampe H, Stawicki S, Wagner T, et al. (January 2006). "Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome". Alcoholism: Clinical and Experimental Research. 30 (1): 86–95. doi:10.1111/j.1530-0277.2006.00013.x. ISSN 0145-6008. PMID 16433735.

[2] "Ogspi "PLO" 2005 Obituary". Ontario Genealogical Society.

[3] "Deaths - Canadian Medical Association Journal". Canadian Medical Association Journal.

[4] "Pioneer in Addiction Treatment Dr. Robert Gordon Bell Leaves Behind a Legacy of Hope and Healing" (PDF). Ontario Federation of Community Mental Health and Addiction Programs. Archived from the original (PDF) on 2014-03-11.

[5] Booze: A Distilled History. Between The Lines. 2003. ISBN 9781896357836.

Treatment of drug dependence (N07B)
Nicotine dependence	Bupropion Cytisine Lobeline Mecamylamine Varenicline AA (Clonidine)
Alcohol dependence	AD inhibitor (Disulfiram Calcium carbimide Hydrogen cyanamide) Acamprosate Opioid antagonists Naltrexone Nalmefene) κ-Opioid receptor antagonists Aticaprant Topiramate AA (Clonidine) Baclofen Metadoxine Phenibut
Opioid dependence	AA (Clonidine Lofexidine) Ibogaine Opioids Buprenorphine (+naloxone) Levacetylmethadol Methadone Dihydrocodeine Dihydroetorphine Hydromorphone (extended-release) Morphine (extended-release) Opioid antagonists (Naltrexone Nalmefene)
Benzodiazepine dependence	AA (Clonidine) Benzodiazepines (Diazepam Lorazepam Chlordiazepoxide Oxazepam) Barbiturates (Phenobarbital)
Research	Salvia divinorum

Calcium carbimide

See also

References